Important Notice to Long-term Shareholders of Elevance Health Inc. (ELV): Grabar Law Office Investigates Claims on Your Behalf

If you purchased Elevance Health Inc. (NYSE: ELV) shares prior to April 18, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/elevance-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085, to learn more.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Elevance Health Inc. (NYSE: ELV), through certain of its officers, represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. In fact, sicker patients with higher acuity tended to remain on Medicaid after redetermination, leading to higher per-patient costs. This increase in cost was occurring at a rate that was not adequately reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. As a result, the Complaint alleges Defendants' positive statements concerning Elevance's close monitoring of the redeterminations, the actuarial soundness of its rates and the prudence of its forecasts were materially misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW: If you purchased Elevance Health Inc. (NYSE: ELV) shares prior to April 18, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/elevance-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $ELV #Elevance

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267433